Philina Lee
Corporate Officer/Principal bij BLUEPRINT MEDICINES CORPORATION
Vermogen: 4 M $ op 31-05-2024
Profiel
Philina Lee is currently the Chief Commercial Officer at Blueprint Medicines Corp.
She previously worked as an Independent Director at Fusion Pharmaceuticals, Inc. from 2021 to 2024.
She also held a position as Head-US Marketing at Algeta ASA. Dr. Lee holds a doctorate degree from the Massachusetts Institute of Technology and an undergraduate degree from the University of Alberta.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 13-03-2024 | 34 729 ( 0.06% ) | 4 M $ | 31-05-2024 |
Actieve functies van Philina Lee
| Bedrijven | Functie | Begin |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Corporate Officer/Principal | 01-01-2021 |
Eerdere bekende functies van Philina Lee
| Bedrijven | Functie | Einde |
|---|---|---|
| FUSN PHAR | Directeur/Bestuurslid | 04-06-2024 |
| ALGETA ASA | Corporate Officer/Principal | - |
Opleiding van Philina Lee
| University of Alberta | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Fusion Pharmaceuticals, Inc.
 Fusion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant in 2014 and is headquartered in Hamilton, Canada. | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
